Last Updated on
The New York State Drug Utilization Review (DUR) Board
April 27, 2016 in Albany
To recommend preferred and non-preferred drugs based on clinical reviews and financial information.
DUR will review Direct Acting Antivirals for Hepatitis C, including Copegus (ribavirin), Daklinza (daclatasvir), Harvoni (ledipasvir/sofosbuvir), Moderiba (ribavirin), Olysio (simeprevir), Rebetol (ribavirin), Ribapak (ribavirin), Ribasphere (ribavirin), ribavirin, Sovaldi (sofosbuvir), Technivie (ombitasvir/paritaprevir/ ritonavir), Viekira Pak (ombitasvir/paritaprevir/ritonavir/ dasabuvir), Zepatier (elbasvir and grazoprevir).
DUR will also review drug utilization in the fee-for-service (FFS) and managed care programs and current clinical criteria in the FFS program.
VOCAL-NY and community leaders will attend the meeting to advocate for unrestricted access to Hepatitis C drug coverage. Transportation will be provided from NYC for those who would like to participate. For more information and to register for a bus seat, email Carlos Rosario at email@example.com
View the meeting agenda hereTags: Hepatitis C NYS Policy